IBB News Alert Nasdaq Biotechnology Ishares (IBB) 273.97 09/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Nasdaq Biotechnology Ishares (IBB) 273.97 $IBB

SmarTrend Watching for Potential Pullback in Shares of iShares Nasdaq Biotechnology Index After 2.80% Gain
Comtex SmarTrend(R) - Wed Sep 24, 3:51PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $272.71 to a high of $279.55. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $277.23 on volume of 1.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

BioShares Plans Two Innovative Biotech ETFs - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Sep 24, 7:00AM CDT
BioShares is looking to launch some very unique biotechnology ETFs soon.

'Fast Money' Recap: How Alibaba Is Hitting Momentum Stocks
at The Street - Tue Sep 16, 4:00AM CDT
The trading panel discussed Chinese stocks, Apple's new phone and whether Darden shares are worth buying.

iShares Nasdaq Biotechnology Index Falls 1.26% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Sep 15, 3:57PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $263.64 to a high of $268.99. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $268.24 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

3 Reasons Actavis plc Stock Could Fall
George Budwell, The Motley Fool - Motley Fool - Mon Sep 15, 10:50AM CDT
Healthcare and biotechnology stocks have put on another amazing show this year, with the closely watched  iShares Nasdaq Biotechnology Index   pushing higher by nearly 19% so far. And certain subsectors, including generic and specialty...

WIT, IBB, EROC, MPX, SEP, TUZ Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Mon Sep 15, 4:16AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Wipro Ltd (NYSE:WIT), Ishares Nasdaq Biotechnology (NASDAQ:IBB), EAGLE ROCK ENERGY PARTNERS (NASDAQ:EROC), Marine Products Corp (NYSE:MPX), Spectra Energy Partners LP (NYSE:SEP), PimCo 1 3 Year Us Treasury Index Fund (NYSE:TUZ) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:

After Yesterday's Rally of 1.85% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Sep 10, 4:08PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $269.51 to a high of $274.64. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $273.23 on volume of 750,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

iShares Nasdaq Biotechnology Index Set to Possibly Pullback After Yesterday's Rally of 1.85%
Comtex SmarTrend(R) - Wed Sep 10, 4:07PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $269.51 to a high of $274.64. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $273.23 on volume of 750,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Biotech ETFs Slip on Gilead Weakness; Buying Opportunity Now? - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Sep 10, 11:00AM CDT
A look at biotech ETFs following some weakness in one of the key companies in the space, Gilead (GILD).

Watch for iShares Nasdaq Biotechnology Index to Potentially Rebound After Falling 1.65% Yesterday
Comtex SmarTrend(R) - Thu Sep 04, 3:50PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $270.23 to a high of $276.22. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $273.85 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

iShares Nasdaq Biotechnology Index Set to Possibly Rebound After Yesterday's Selloff of 1.65%
Comtex SmarTrend(R) - Thu Sep 04, 3:50PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $270.23 to a high of $276.22. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $273.85 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?

After Recent Surge, Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?

Biotech Stock Boom Times Are Back
at The Street - Tue Aug 26, 6:00AM CDT
The iShares Nasdaq Biotechnology ETF closed at 272.63 Monday, less than one point below the year (and all-time) closing high reached on Feb. 25.

'Fast Money' Recap: Next Stop, S&P 2,100?
at The Street - Tue Aug 26, 4:00AM CDT
The trading panel looked at banks and the top buy and sell candidates for right now.

Look for Shares of iShares Nasdaq Biotechnology Index to Potentially Pullback after Yesterday's 2.33% Rise
Comtex SmarTrend(R) - Mon Aug 25, 4:07PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $268.75 to a high of $272.88. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $268.60 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Implantica's U.S. Launch Arrives With Cash Still to Burn

Updated Category News Views 0

RefluxStop has finally stepped onto American soil, and that changes the conversation around Implantica in a very real way. FDA Premarket Approval arrived on August 20, then the first U.S. procedures were completed in early November at the University of Southern California. For a small medtech outfit, clearing that regulatory gate and getting actual patients treated are...

Continue Reading
Nellie's 50% Booking Jump Reveals a Quieter Luxury

Updated Category News Views 141

Silicon Valley’s rich are apparently tired of performing wealth for strangers, and frankly, that tracks. Nellie’s 2027 forecast says its mostly tech-money clientele is moving past the old trophy case of private jets, famous resort towns, and suites priced like small houses. The prize now is privacy, a clean schedule, and somebody competent fixing the ugly little...

Continue Reading
Hyundai’s Third SUV Crown Matters Beyond the Trophy

Updated Category News Views 0

A Three-Year Streak Is Not Just Decorative Three straight SUV-brand wins can make even a cynical car watcher pause. Hyundai has been named U.S. News & World Report’s 2027 Best SUV Brand after editors assessed vehicles from 39 brands, and that is a useful bit of outside validation in a segment where nearly everybody is throwing sheet metal, screens, and marketing dollars...

Continue Reading
NextPatient’s KLAS Marks Signal Specialty Workflow Fit

Updated Category News Views 79

A 93.3 score in healthcare software deserves a second look. Not a victory lap, not a drumroll—just a serious look at whether the product is solving an annoying, expensive operational problem for specialty practices. NextPatient’s recognition in the 2026 KLAS Emerging Solutions Top 20 Report lands in that category. The company placed in the top five for improving...

Continue Reading
illumine Targets Childcare Chain Control and Risk Gaps

Updated Category News Views 131

Expansion Gets Messy Before It Gets Impressive Childcare operators do not usually stumble because they forgot how to care for children; they stumble because the back office fractures as the network grows. One center handles fees one way, another lets enrollment leads work a different funnel, and headquarters discovers too late that its reports are arguing with each other....

Continue Reading
Rehab Equipment Growth Meets a Brutal Access Gap

Updated Category News Views 151

Rehabilitation demand is piling up faster than the equipment can reach people. That is the uncomfortable fact sitting beneath Wissen Research's forecast for a global rehabilitation equipment market rising from $19.1 billion in 2026 to $25.8 billion by 2031, a 6.2% annual growth rate. It is a respectable expansion story, not some rocket-ship fairy tale. More important, it...

Continue Reading
Sinopec's Green Fuel Push Meets a Hard Reality Check

Updated Category News Views 30

A refinery giant talking about green jet fuel at a climate summit is exactly the sort of thing that makes old energy hands squint first—and then check the asset list. Sinopec did bring more than lofty language to its Nov. 16 COP31 side event in Antalya: it brought long-range energy forecasts, named fuel-production routes, hydrogen infrastructure and operating projects....

Continue Reading
Yatsen’s November 25 Report Is the Real Beauty Test

Updated Category News Views 90

Beauty shelves can hide a lot of sins, but earnings day tends to drag them into fluorescent light. Yatsen will release unaudited third-quarter 2026 financial results before the U.S. market opens on Wednesday, November 25, then management will take questions at 7:30 a.m. Eastern Time. For anyone following NYSE:YSG, this is not a results story yet. It is a calendar marker,...

Continue Reading
Dutch Solar Homes Face a 2027 Net Metering Reset Ahead

Updated Category News Views 24

A policy switch buried in a Dutch calendar is about to rearrange millions of kitchen-table energy calculations. On 1 January 2027, the Netherlands ends net metering, or salderingsregeling, and households with solar panels will no longer offset exported power against electricity bought from the grid. That is not some abstract regulatory footnote. It changes the value of...

Continue Reading
Misunderstood Brands Bets Small Cans Can Scale Growth

Updated Category News Views 190

A tiny cocktail can is a brutal little test of whether a spirits brand has legs. Misunderstood Brands is putting four 100mL offerings on the shelf just as its Wegmans distribution expands across the East Coast, and that combination matters more than another glossy flavor announcement. The company is trying to turn products people discovered in bars and restaurants into...

Continue Reading

Top 5 Most Recently Viewed Articles

DallasNews Shareholders Urged to Support Merger Deal with Hearst

Updated Category News Views 101

Overview of the DallasNews and Hearst Merger DallasNews Corporation, the parent company of The Dallas Morning News, has proposed a significant merger with Hearst, a prominent media organization. This merger offers an enticing cash value of $15.00 per share, bringing impressive benefits to shareholders. Recently, Glass Lewis, an independent proxy advisory firm, recommended...

Continue Reading
GitLab Director Karen Blasing's Recent Stock Transactions Explained

Updated Category News Views 154

Analyzing the Recent Insider Trading at GitLab GitLab Inc. (NASDAQ:GTLB) has recently drawn the attention of investors and market analysts due to stock transactions made by its director, Karen Blasing. A recent filing with the U.S. Securities and Exchange Commission revealed that Blasing sold a considerable amount of her stock holdings, totaling more than $173,000....

Continue Reading
Avenue Living's Strategic $350 Million Debenture Offering

Updated Category News Views 202

Avenue Living Announces $350 Million Senior Unsecured Debenture Offering Avenue Living (2014) LP has recently announced a significant financial move with a $350 million offering of Series B senior unsecured debentures. This opportunity is set to be priced at par and is due by September 25, 2028, indicating a long-term strategy for the company’s financing needs. Details...

Continue Reading
Fagron Reports Strong Financial Growth with Strategic Outlook

Updated Category News Views 349

Fagron's Remarkable Financial Performance Fagron, a global leader in pharmaceutical compounding, recently showcased its impressive results for the period ending December 31, 2024. The company’s financial achievements highlight significant growth across various sectors and regions in the pharmaceutical industry, reinforcing its commitment to excellence and innovation....

Continue Reading
Dizal's Sunvozertinib Receives Breakthrough Therapy Designation

Updated Category News Views 444

Dizal's Sunvozertinib Achieves Breakthrough Therapy Designation Dizal, a biopharmaceutical company dedicated to developing innovative cancer and immunological therapies, recently announced an important milestone. The Center for Drug Evaluation of China's National Medical Products Administration has granted Breakthrough Therapy Designation for sunvozertinib, aimed at...

Continue Reading